GALAPAGOS NV/S (GLPG) Now Covered by Analysts at Raymond James
Raymond James began coverage on shares of GALAPAGOS NV/S (NASDAQ:GLPG) in a research note published on Wednesday, November 14th, Marketbeat reports. The brokerage issued a strong-buy rating and a $157.00 price objective on the biotechnology company’s stock.
A number of other equities analysts have also issued reports on the company. Zacks Investment Research lowered GALAPAGOS NV/S from a buy rating to a hold rating in a research note on Tuesday, November 13th. ValuEngine upgraded GALAPAGOS NV/S from a buy rating to a strong-buy rating in a research report on Saturday, November 10th. Morgan Stanley increased their price objective on GALAPAGOS NV/S from $127.00 to $131.00 and gave the company an overweight rating in a research report on Monday, November 5th. Nomura increased their price objective on GALAPAGOS NV/S from $124.00 to $140.00 and gave the company a buy rating in a research report on Tuesday, October 30th. Finally, Credit Suisse Group cut their price objective on GALAPAGOS NV/S from $92.00 to $90.00 and set a hold rating for the company in a research report on Friday, October 26th. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $121.44.
GLPG stock traded down $1.10 on Wednesday, reaching $100.15. The company’s stock had a trading volume of 82,705 shares, compared to its average volume of 75,832. The firm has a market capitalization of $5.19 billion, a price-to-earnings ratio of -37.94 and a beta of 1.89. GALAPAGOS NV/S has a 52 week low of $84.13 and a 52 week high of $122.28.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Financial Gravity Wealth Inc. lifted its holdings in shares of GALAPAGOS NV/S by 64.1% in the third quarter. Financial Gravity Wealth Inc. now owns 2,261 shares of the biotechnology company’s stock valued at $225,000 after purchasing an additional 883 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of GALAPAGOS NV/S in the third quarter valued at $256,000. AMP Capital Investors Ltd purchased a new stake in shares of GALAPAGOS NV/S in the second quarter valued at $221,000. Provident Investment Management Inc. purchased a new stake in shares of GALAPAGOS NV/S in the second quarter valued at $249,000. Finally, Moody National Bank Trust Division purchased a new stake in shares of GALAPAGOS NV/S in the third quarter valued at $394,000. Institutional investors own 18.13% of the company’s stock.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Further Reading: What type of investment options does a Roth IRA provide?
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.